Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

Recent Analyst Ratings for $DYN

$DYN Press Releases

$DYN Analyst Ratings

$DYN Insider Trading

$DYN Large Ownership Changes

Chat with this insight

Fastest customizable press release news feed in the world

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Dyne Therapeutics downgraded by JP Morgan with a new price target

Chardan Capital Markets reiterated coverage on Dyne Therapeutics with a new price target

Morgan Stanley initiated coverage on Dyne Therapeutics with a new price target

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Incerti Carlo exercised 16,500 shares at a strike of $8.69 and sold $474,045 worth of shares (16,500 units at $28.73) (SEC Form 4)

Director Rhodes Jason P sold $25,884 worth of shares (782 units at $33.10) (SEC Form 4)

SVP, Head of Finance & Admin. Scalzo Richard William sold $77,127 worth of shares (2,735 units at $28.20), decreasing direct ownership by 3% to 95,833 units (SEC Form 4)

This live feed shows all institutional transactions in real time.

11/14/24 7:00:28 AM ET

$DYN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DYN alert in real time by email

SC 13G/A 1 d912866dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Dyne Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

26818M108

(CUSIP Number)

SEPTEMBER 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐	Rule 13d-1(b)

☐	Rule 13d-1(c)

☒	Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 76029N106		13G		Page 2 of 9 Pages

1	This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


CUSIP No. 76029N106		13G		Page 3 of 9 Pages

2	This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


CUSIP No. 76029N106		13G		Page 4 of 9 Pages

3	This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


CUSIP No. 76029N106		13G		Page 5 of 9 Pages

4	This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


CUSIP No. 76029N106		13G		Page 6 of 9 Pages

5	This percentage is calculated based upon 100,400,798 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.


CUSIP No. 76029N106		13G		Page 7 of 9 Pages

Item 1(a).

Name of Issuer:

Dyne Therapeutics, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices:

1560 Trapelo Road, Waltham, MA 02451

Item 2(a).

Name of Person Filing:

This Statement is being filed by ForDyne B.V. (“ForDyne”), Forbion Capital Fund IV Coöperatief U.A. (“Forbion IV COOP”), Forbion IV Management B.V. (“Forbion IV”), the director of Forbion IV COOP, Forbion Growth Opportunities Fund II Coöperatief U.A. (“Forbion II COOP”) and Forbion Growth II Management B.V. (“Forbion II”), the director of Forbion II COOP. ForDyne is a joint investment vehicle wholly owned by Forbion IV COOP and Forbion II COOP, but does not exercise voting or dispositive power over the shares held on behalf of Forbion IV COOP and Forbion II COOP. The foregoing entities are sometimes referred to collectively herein as the “Reporting Persons”.

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.

Item 2(c).

Citizenship:

ForDyne B.V. – The Netherlands

Forbion IV COOP – The Netherlands

Forbion IV – The Netherlands

Forbion II COOP – The Netherlands

Forbion II – The Netherlands

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.0001 per share

Item

2(e). CUSIP Number: 26818M108

Item 3.

Item 4.

Ownership.


(a)-(b)		Amount beneficially owned, Percent of class: ForDyne directly holds 5,795,364 shares of Common Stock, representing approximately 5.8% of the outstanding Common Stock. ForDyne is a joint investment vehicle wholly owned by Forbion IV COOP and Forbion II COOP, but does not exercise voting or dispositive power over the shares held on behalf of Forbion IV COOP and Forbion II COOP. Forbion IV COOP directly holds 158,705 shares of Common


CUSIP No. 76029N106		13G		Page 8 of 9 Pages


		Stock, and may be deemed to beneficially own 4,366,793 shares of Common Stock held directly by ForDyne, representing approximately 4.7% of the outstanding Common Stock. Forbion II COOP may be deemed to beneficially own 1,428,571 shares are held directly by ForDyne, representing approximately 1.4% of the outstanding Common Stock. Forbion IV, the director of Forbion IV COOP, may be deemed to have voting and investment power over the shares beneficially owned by Forbion IV COOP. Forbion II, the director of Forbion II COOP, may be deemed to have voting and investment power over the shares beneficially owned by Forbion II COOP.

(c)

Number of shares as to which such person has:


Reporting Person	Sole Voting Power		Shared Voting Power		Sole Dispositive Power		Shared Dispositive Power
ForDyne		0		5,795,364		0		5,795,364
Forbion IV COOP		0		4,525,498		0		4,525,498
Forbion IV		0		4,525,498		0		4,525,498
Forbion II COOP		0		1,428,571		0		1,428,571
Forbion II		0		1,428,571		0		1,428,571

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

The Reporting Persons are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a “group” for purposes of Rule 13d-5 or for any other purpose.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item

10. Certification.

Not applicable .


CUSIP No. 76029N106		13G		Page 9 of 9 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 14, 2024


FORDYNE B.V.

By: Forbion International Management B.V., its director

By:		/s/ V. van Houten /s/ H.A. Slootweg
		Name: V. van Houten and H.A. Slootweg
		Title: Directors

FORBION CAPITAL FUND IV COÖPERATIEF U.A.

By:		Forbion IV Management B.V., its director

By:		FCPM III Services B.V., its director

By:		/s/ V. van Houten /s/ H.A. Slootweg
		Name: V. van Houten and H.A. Slootweg
		Title: Directors

FORBION IV MANAGEMENT B.V.

By:		FCPM III Services B.V., its director

By:		/s/ V. van Houten /s/ H.A. Slootweg
		Name: V. van Houten and H.A. Slootweg
		Title: Directors

FORBION CAPITAL FUND II COÖPERATIEF U.A.

By:		Forbion II Management B.V., its director

By:		FCPM III Services B.V., its director

By:		/s/ V. van Houten /s/ H.A. Slootweg
		Name: V. van Houten and H.A. Slootweg
		Title: Directors

FORBION II MANAGEMENT B.V.

By:		FCPM III Services B.V., its director

By:		/s/ V. van Houten /s/ H.A. Slootweg
		Name: V. van Houten and H.A. Slootweg
		Title: Directors

Get the next $DYN alert in real time by email

Date	Price Target	Rating	Analyst
10/24/2024	$43.00 → $35.00	Overweight → Neutral	JP Morgan
5/21/2024	$31.00 → $42.00	Buy	Chardan Capital Markets
4/30/2024	$40.00	Overweight	Morgan Stanley
2/20/2024	$36.00	Buy	H.C. Wainwright
2/27/2023	$16.00 → $27.00	Outperform → Strong Buy	Raymond James
2/15/2023	$34.00	Outperform	Oppenheimer
1/26/2023	$33.00	Buy	Guggenheim
7/20/2022	$17.00	Buy	Chardan Capital Markets

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

ForDyne B.V.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

The Netherlands